Exploratory analysis of EGFR FISH criteria in Japanese non-small cell lung cancer patients treated with gefitinib

被引：0
|
作者：
Kazuo, K.
Morrison, L. E.
Kimura, H.
Sone, T.
Araya, T.
Tamori, S.
Tanbo, Y.
Fujimura, M.
Speake, G.
Holloway, B. R.
机构：
[1] Kanazawa Univ, Kanazawa, Ishikawa, Japan
[2] Abbott Mol Inc, Des Plaines, IL USA
[3] AstraZeneca, Macclesfield, Cheshire, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7599
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - A retrospective analysis: JMTO LC03-02
    Nakagawa M.
    Nishimura T.
    Teramukai S.
    Tada H.
    Tanaka F.
    Yanagihara K.
    Furuse K.
    Wada H.
    Fukushima M.
    BMC Research Notes, 2 (1)
  • [22] Analysis of the response and toxicity to gefitinib of non-small cell lung cancer
    Konishi, J
    Yamazaki, K
    Kinoshita, I
    Isobe, H
    Ogura, S
    Sekine, S
    Ishida, T
    Takashima, R
    Nakadate, M
    Nishikawa, S
    Hattori, T
    Asahina, H
    Imura, M
    Kikuchi, E
    Kikuchi, J
    Shinagawa, N
    Yokouchi, H
    Munakata, M
    Dosaka-Akita, H
    Nishimura, M
    ANTICANCER RESEARCH, 2005, 25 (1B) : 435 - 441
  • [23] Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib
    Zucali, Paolo A.
    Giovannetti, Elisa
    Peters, Godefridus
    Cortesi, Filippo
    D'Incecco, Armida
    Smit, Egbert
    Falcone, Alfredo
    Burgers, Sjaak
    Santoro, Armando
    Danesi, Romano
    Giaccone, Giuseppe
    Tibaldi, Carmelo
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S510 - S510
  • [24] Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non-Small Cell Lung Cancer Patients Treated with Gefitinib
    Giovannetti, Elisa
    Zucali, Paolo A.
    Peters, Godefridus J.
    Cortesi, Filippo
    D'Incecco, Armida
    Smit, Egbert F.
    Falcone, Alfredo
    Burgers, Jacobus A.
    Santoro, Armando
    Danesi, Romano
    Giaccone, Giuseppe
    Tibaldi, Carmelo
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (03) : 581 - 593
  • [25] EGFR/KRAS-GERMLINE MUTATION ANALYSES IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH GEFITINIB/ERLOTINIB
    Tibaldi, C.
    Giovannetti, E.
    Vasile, E.
    Torti, D.
    Gallegos-Ruiz, M. I.
    Nannizzi, S.
    Del Tacca, M.
    Peters, G. J.
    Falcone, A.
    Danesi, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 106 - 106
  • [26] Gefitinib therapy for non-small cell lung cancer
    Birnbaum A.
    Ready N.
    Current Treatment Options in Oncology, 2005, 6 (1) : 75 - 81
  • [27] Gefitinib for advanced non-small cell lung cancer
    Sim, Esther H. A.
    Yang, Ian A.
    Wood-Baker, Richard
    Bowman, Rayleen V.
    Fong, Kwun M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (01):
  • [28] Gefitinib in advanced non-small cell lung cancer
    Sharma, R
    Boyer, M
    Clarke, S
    Millward, M
    INTERNAL MEDICINE JOURNAL, 2005, 35 (02) : 77 - 82
  • [29] Gefitinib first or gefitinib second -: Is timing everything in the treatment of EGFR mutant non-small cell lung cancer?
    Jaenne, Pasi A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 178 (08) : 783 - 785
  • [30] ANALYSIS OF GEFITINIB ON BRAIN METASTASES IN PATIENTS WITH NON-SMALL LUNG CANCER
    Baihao, H.
    RESPIROLOGY, 2011, 16 : 132 - 132
12345